CCAAT/Enhancer binding protein β silencing mitigates glial activation and neurodegeneration in a rat model of Parkinson’s disease-Reference-Cited by-同舟云学术

CCAAT/Enhancer binding protein β silencing mitigates glial activation and neurodegeneration in a rat model of Parkinson’s disease

Published:2017-10-19 Issue:1 Volume:7 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Morales-Garcia Jose A.^ORCID,Gine Elena,Hernandez-Encinas Elena,Aguilar-Morante Diana,Sierra-Magro Ana,Sanz-SanCristobal Marina,Alonso-Gil Sandra,Sanchez-Lanzas Raul,Castaño Jose G.,Santos Angel,Perez-Castillo Ana^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-017-13269-4.pdf

Reference49 articles.

1. Ramji, D. P. & Foka, P. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J 365, 561–575 (2002).

2. Tsukada, J., Yoshida, Y., Kominato, Y. & Auron, P. E. The CCAAT/enhancer (C/EBP) family of basic-leucine zipper (bZIP) transcription factors is a multifaceted highly-regulated system for gene regulation. Cytokine 54, 6–19, https://doi.org/10.1016/j.cyto.2010.12.019 (2011).

3. Aguilar-Morante, D., Morales-Garcia, J. A., Santos, A. & Perez-Castillo, A. CCAAT/enhancer binding protein beta induces motility and invasion of glioblastoma cells through transcriptional regulation of the calcium binding protein S100A4. Oncotarget 6, 4369–4384 (2015).

4. Croniger, C., Leahy, P., Reshef, L. & Hanson, R. W. C/EBP and the control of phosphoenolpyruvate carboxykinase gene transcription in the liver. The Journal of biological chemistry 273, 31629–31632 (1998).

5. Croniger, C. M. et al. Mice with a deletion in the gene for CCAAT/enhancer-binding protein beta have an attenuated response to cAMP and impaired carbohydrate metabolism. The Journal of biological chemistry 276, 629–638 (2001).

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. C/EBPβ: A transcription factor associated with the irreversible progression of Alzheimer's disease;CNS Neuroscience & Therapeutics;2024-04

2. Pharmaceutical Considerations of Translabial Formulations for Treatment of Parkinson’s Disease: A Concept of Drug Delivery for Unconscious Patients;Current Drug Delivery;2023-10

3. C/EBPβ Regulates TFAM Expression, Mitochondrial Function and Autophagy in Cellular Models of Parkinson’s Disease;International Journal of Molecular Sciences;2023-01-11

4. Multi-Target Effects of ß-Caryophyllene and Carnosic Acid at the Crossroads of Mitochondrial Dysfunction and Neurodegeneration: From Oxidative Stress to Microglia-Mediated Neuroinflammation;Antioxidants;2022-06-18

5. Inhibition of the CEBPβ-NFκB interaction by nanocarrier-packaged Carnosic acid ameliorates glia-mediated neuroinflammation and improves cognitive function in an Alzheimer’s disease model;Cell Death & Disease;2022-04-07